ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Mainz BioMed NV

Mainz BioMed NV (MYNZ)

0.2499
-0.0042
(-1.65%)
At close: September 19 4:00PM
0.25
0.0001
( 0.04% )
After Hours: 6:11PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.25
Bid
0.25
Ask
0.27
Volume
1,793,080
0.243 Day's Range 0.28
0.2271 52 Week Range 3.3923
Market Cap
Previous Close
0.2541
Open
0.257
Last Trade Time
18:11:58
Financial Volume
$ 472,678
VWAP
0.263612
Average Volume (3m)
1,655,187
Shares Outstanding
21,165,482
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
895k
Net Profit
-26.3M

About Mainz BioMed NV

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Sector
Testing Laboratories
Industry
Testing Laboratories
Headquarters
Amsterdam, North Holland, Nld
Founded
-
Mainz BioMed NV is listed in the Testing Laboratories sector of the NASDAQ with ticker MYNZ. The last closing price for Mainz BioMed NV was $0.25. Over the last year, Mainz BioMed NV shares have traded in a share price range of $ 0.2271 to $ 3.3923.

Mainz BioMed NV currently has 21,165,482 shares outstanding. The market capitalization of Mainz BioMed NV is $5.38 million.

MYNZ Latest News

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (โ€œMainz Biomedโ€ or the โ€œCompanyโ€), a molecular genetics diagnostic company specializing in...

Mainz Biomed Partners with Liquid Biosciencesย to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (โ€œMainz Biomedโ€ or the โ€œCompanyโ€), a molecular genetics diagnostic company specializing in...

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today...

Micro Cap Bid Up Following FDA Submission Announcement

A medical company based out of Germany is already turning heads during Tuesday’s premarket hours after the company announced the submission of its application to the U.S To read the full...

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal...

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia...

Mainz Biomed Reports Results of 2024 Annual General Meeting

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06455-20.52137974880.314550.3340.227125260980.28404767CS
4-0.1258-33.4752527940.37580.460.227121385910.33679208CS
12-0.149-37.3433583960.3990.55990.227116551870.37848739CS
26-0.75-7511.130.22718602170.41751839CS
52-3.03-92.37804878053.283.39230.22715132080.55712188CS
156-14.1-98.257839721314.35300.22712678744.53881907CS
260-14.1-98.257839721314.35300.22712678744.53881907CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LFLYLeafly Holdings Inc
$ 3.78
(111.17%)
4.68M
AENTAlliance Entertainment Holding Corporation
$ 2.80
(37.25%)
122.42k
TNONTenon Medical Inc
$ 6.45
(28.23%)
2.7M
AEMDAethlon Medical Inc
$ 0.4949
(26.90%)
8.43M
LDTCLeddarTech Holdings Inc
$ 0.3649
(22.45%)
180.12k
EJHE Home Household Service Holdings Ltd
$ 0.077
(-21.11%)
8.68M
KOPNKopin Corporation
$ 0.8004
(-16.98%)
191.23k
NCINeo Concept International Group Holdings Ltd
$ 0.74
(-11.90%)
1.57M
RZLVRezolve AI Ltd
$ 6.3022
(-9.97%)
40.17k
ARQArq Inc
$ 5.58
(-9.56%)
87.77k
EJHE Home Household Service Holdings Ltd
$ 0.077
(-21.11%)
8.68M
AEMDAethlon Medical Inc
$ 0.50
(28.21%)
8.43M
HSTHost Hotels and Resorts Inc
$ 18.53
(0.00%)
6.45M
LFLYLeafly Holdings Inc
$ 3.78
(111.17%)
4.68M
SQQQProShares UltraPro Short QQQ
$ 7.79
(0.39%)
4.62M

MYNZ Discussion

View Posts
mining101 mining101 8 hours ago
Last uptick?
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 day ago
MYNZ new 52 week low
๐Ÿ‘๏ธ0
skydog526 skydog526 2 days ago
Looks bad. No touch
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 2 days ago
Any news on this? FDA decision?
๐Ÿ‘๏ธ0
gatorhistory gatorhistory 6 days ago
Waiting for news. Financials and fda response anyday imo
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 6 days ago
Is this stock losing traction? Where is the FDA approval?
๐Ÿ‘๏ธ0
Dcab Dcab 1 week ago
Appears they got the FDA approval because the bleeding of the last few days has reversed. JMO
๐Ÿ‘๏ธ0
Dcab Dcab 1 week ago
Obviously there will be a buyout with the FDA approval and a big run up. They always drive the pps down right before the run up to buy as cheap possible. Always some sort of manipulation going on. JMHO.
๐Ÿ‘๏ธ0
Dcab Dcab 1 week ago
Obviously there will be a buyout with the FDA approval and a big run up. They always drive the pps down right before the run up to buy as cheap possible. Always some sort of manipulation going on. JMHO.
๐Ÿ‘๏ธ0
81vette 81vette 1 week ago
Dunno,shorts tearing into it today like a monkey eating a cupcake,shares to short went way up
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 1 week ago
Will the FDA approve?
๐Ÿ‘๏ธ0
ollik78 ollik78 1 week ago
Will be interesting AH
Approval or Not
👍️ 1
mining101 mining101 1 week ago
Ready
๐Ÿ‘๏ธ0
81vette 81vette 1 week ago
Charting up,FDA news expected,
๐Ÿ‘๏ธ0
gatorhistory gatorhistory 2 weeks ago
Bring on the fda news!
๐Ÿ‘๏ธ0
mining101 mining101 2 weeks ago
Little Fomo
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 3 weeks ago
Will the FDA approveโ€ฆ?
๐Ÿ‘๏ธ0
mining101 mining101 3 weeks ago
Chart lines soon crossing
๐Ÿ‘๏ธ0
georgie18 georgie18 3 weeks ago
MYNZ...39s clearing here...Off my .44 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 655296

Monday, August 26, 2024 4:42:19 PM

Post#
655298
of 655457
MYNZ...44...on the 50MA Break...🥳
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
Loading zone, IMO .
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 3 weeks ago
Waiting on FDA decision
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
Not in a hurry !
๐Ÿ‘๏ธ0
gatorhistory gatorhistory 3 weeks ago
Apparently no. Lol
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
Can we see so 50s today !
๐Ÿ‘๏ธ0
georgie18 georgie18 3 weeks ago
MYNZ...44...on the 50MA Break...🥳
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
45s looks like breakout on the way !
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
You welcome, still waiting on volume, I think after hours should be interesting, GL .
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 3 weeks ago
Ok thanks
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
๐Ÿ” $MYNZ โ€™s ColoAlert test could set a new standard in cancer screening. Analysts target $1.50, but buzz is $5-$10 per share. Just loaded up! $EXAS $NVTA $GH #CancerDetection #HealthTech #Biotech #BuyTheDip #ToTheMoon #BuyTheDip #ToTheMoon $COIN $NFLX $ATVI #CamperXBecky pic.twitter.com/DDCBCdmeMI— Michael Johnson (@HenryV64655) August 26, 2024
👍️ 1
mining101 mining101 3 weeks ago
Nice outlook
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 3 weeks ago
have you heard any projections on share price if the FDA approves?
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
42s up
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
Volume in !
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 3 weeks ago
Creeping up !
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 4 weeks ago
Iโ€™m not sure if thatโ€™s good or bad, maybe people loading, waiting on news, the last PR was about a month ago, and itโ€™s moving on Friday, thatโ€™s what got my attention, hopefully we will get some news next week, itโ€™s about time, IMO .
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 4 weeks ago
Quiet board
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 4 weeks ago
Coming off the 52WL, letโ€™s see if we can get some attention, in for now !
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 1 month ago
Invest at your own risk!!!


https://stocktwits.com/BreakoutMaster8/message/583420341
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 month ago
MYNZ new 52 week low
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 1 month ago
$MYNZ is about to explode! Just saw an alert: #FDA submission is done, and theyโ€™re targeting massive partnerships! ๐Ÿš€๐Ÿ“ท #DiamondHands #BuyTheDip #HBDSurBeryliyaciaga #BalenciagaxMilk $AAPL $GME #8YearsWithBLACKPINK #internationalcatday $AMC $AMZN #Biden #ToTheMoon #YOLO pic.twitter.com/VpWDEA9utO— Julia Thompson (@ouma15) August 8, 2024
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 1 month ago
https://www.rttnews.com/3458713/mainz-biomed-seeks-fda-breakthrough-status-for-next-generation-crc-screening-test.aspx
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 1 month ago
This board is very quiet
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 1 month ago
https://finance.yahoo.com/quote/MYNZ/
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 2 months ago
https://mainzbiomed.com/mainz-biomed-announces-submission-for-fda-breakthrough-device-designation-for-its-next-generation-crc-screening-test/
๐Ÿ‘๏ธ0
tiger_trader tiger_trader 2 months ago
Is there a projected target price on this?
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
MYNZ......................https://stockcharts.com/h-sc/ui?s=MYNZ&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
tw0122 tw0122 2 months ago
submitted its application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for its non-invasive Next Generation colorectal cancer (CRC) product including the Companyโ€™s novel portfolio of mRNA biomarkers. Subject to the FDAโ€™s review, a Breakthrough Device Designation could significantly accelerate approval.
The regulatory submission follows consistently excellent read-outs of its clinical studies ColoFuture and eAArly Detect, as well as data from a pooled study including both the European and the US arm that were presented at ASCO 2024. On the basis of these studies Mainz Biomed has now defined the final configuration of its Next Generation Test integrating the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm that the Company plans to use in its Next Generation product, and the FDA premarket approval study.

The configuration of the Next Generation Test was tested in a clinical setting. The analysis involved 295 clinical subjects from 21 specialized gastroenterology centers across the United States and highlighted the remarkable efficacy of Mainz Biomed's multimodal screening test. This combination enables precise differentiation among colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas, and samples with no pathological findings.

Key Findings

Sensitivity for Colorectal Cancer: 97% (95% confidence interval: 83.3-99.9)
Sensitivity for Advanced Precancerous Lesions: 88% (95% confidence interval: 77.2-94.5)
Specificity: 93% (95% confidence interval: 88.4-98.3)
Guido Baechler, Chief Executive Officer at Mainz Biomed, commented, โ€œOn the back of our extremely positive clinical results in all our recent studies, finalizing the test which will be used in the pivotal ReconAAsense study and approval process has been an elementary milestone for our Company. Our Next Generation Test has shown a significant improvement in sensitivity for advanced adenomas and high-grade dysplasias, combined with high sensitivity and specificity for CRC. Moreover, we believe that our unique decentralized model of working with third party laboratory partners provides better access to underserved communities and our simple collection process will increase the adherence to testing. These benefits support our mission to transform colorectal cancer screening practices and reduce global cancer mortality rates.โ€

The FDAโ€™s Breakthrough Devices Designation is a program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. It is intended to allow patients and health care providers timely access to medical devices by speeding up development, assessment, and review for premarket approval, 510(k) clearance, and De Novo marketing authorizations. Breakthrough Devices must meet the FDAโ€™s rigorous standards for device safety and effectiveness in order to be authorized for marketing.

Please visit Mainz Biomedโ€™s official website for investors at mainzbiomed.com/investors/ or subscribe to our news alert to keep up to date on our pivotal FDA PMA clinical trial ReconAAsense and further corporate news.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market oppo
๐Ÿ‘๏ธ0
tw0122 tw0122 2 months ago
MYNZ .68 + 40%
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
MYNZ new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
MYNZ new 52+ low
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock